[
  {
    "ts": "2026-02-13T05:36:38+00:00",
    "headline": "The 5 Most Interesting Analyst Questions From Biogen’s Q4 Earnings Call",
    "summary": "Biogen’s fourth-quarter results were received positively by the market, as the company exceeded Wall Street’s revenue and non-GAAP profit expectations despite a year-over-year decline in sales. Management attributed performance to robust growth in its newer product portfolio, particularly Lekembi, Skyclaris, Xerxuve, and Calcadi, which collectively surpassed $1 billion in annual revenue. CEO Christopher Viehbacher pointed to successful expansion of VUMERITY within the multiple sclerosis segment",
    "url": "https://finance.yahoo.com/news/5-most-interesting-analyst-questions-053638140.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "0556a31a-97db-34e6-9771-2ba435b0b30a",
      "content": {
        "id": "0556a31a-97db-34e6-9771-2ba435b0b30a",
        "contentType": "STORY",
        "title": "The 5 Most Interesting Analyst Questions From Biogen’s Q4 Earnings Call",
        "description": "",
        "summary": "Biogen’s fourth-quarter results were received positively by the market, as the company exceeded Wall Street’s revenue and non-GAAP profit expectations despite a year-over-year decline in sales. Management attributed performance to robust growth in its newer product portfolio, particularly Lekembi, Skyclaris, Xerxuve, and Calcadi, which collectively surpassed $1 billion in annual revenue. CEO Christopher Viehbacher pointed to successful expansion of VUMERITY within the multiple sclerosis segment",
        "pubDate": "2026-02-13T05:36:38Z",
        "displayTime": "2026-02-13T05:36:38Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/3e9471166a0d4ee8c41ab9eef8ac261c",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "BIIB Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/RI16PwyrPkPhFQpSFVHcpw--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/3e9471166a0d4ee8c41ab9eef8ac261c.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IR.mhpWSH09RyIH1vck_EQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/3e9471166a0d4ee8c41ab9eef8ac261c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/5-most-interesting-analyst-questions-053638140.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/5-most-interesting-analyst-questions-053638140.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T11:23:22+00:00",
    "headline": "Biogen's (NASDAQ:BIIB) Soft Earnings Don't Show The Whole Picture",
    "summary": "Soft earnings didn't appear to concern Biogen Inc.'s ( NASDAQ:BIIB ) shareholders over the last week. We did some...",
    "url": "https://finance.yahoo.com/news/biogens-nasdaq-biib-soft-earnings-112322087.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "55fe89ff-1dda-30a7-b3a7-5b2b682e21b7",
      "content": {
        "id": "55fe89ff-1dda-30a7-b3a7-5b2b682e21b7",
        "contentType": "STORY",
        "title": "Biogen's (NASDAQ:BIIB) Soft Earnings Don't Show The Whole Picture",
        "description": "",
        "summary": "Soft earnings didn't appear to concern Biogen Inc.'s ( NASDAQ:BIIB ) shareholders over the last week. We did some...",
        "pubDate": "2026-02-13T11:23:22Z",
        "displayTime": "2026-02-13T11:23:22Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/I2k3PKJsWIEX9xgEQz8JwQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tmSjpFKmBAT61w1lG5.BLQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/biogens-nasdaq-biib-soft-earnings-112322087.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/biogens-nasdaq-biib-soft-earnings-112322087.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T15:27:55+00:00",
    "headline": "Dianthus Therapeutics Conference: DNTH Eyes Q2 2026 CIDP Phase 3 Interim Readout, Expands Pipeline Plans",
    "summary": "Dianthus Therapeutics (NASDAQ:DNTH) executives used a Biotech Summit 2026 discussion to outline upcoming clinical catalysts for its lead complement inhibitor program and provide updated timing on pipeline plans, while also emphasizing what they see as potential competitive advantages in neuromuscula",
    "url": "https://www.marketbeat.com/instant-alerts/dianthus-therapeutics-conference-dnth-eyes-q2-2026-cidp-phase-3-interim-readout-expands-pipeline-plans-2026-02-13/?utm_source=yahoofinance&utm_medium=yahoofinance",
    "source": "MarketBeat",
    "provider": "yfinance",
    "raw": {
      "id": "af3dd98e-d052-3361-b1a4-0456502fede7",
      "content": {
        "id": "af3dd98e-d052-3361-b1a4-0456502fede7",
        "contentType": "STORY",
        "title": "Dianthus Therapeutics Conference: DNTH Eyes Q2 2026 CIDP Phase 3 Interim Readout, Expands Pipeline Plans",
        "description": "",
        "summary": "Dianthus Therapeutics (NASDAQ:DNTH) executives used a Biotech Summit 2026 discussion to outline upcoming clinical catalysts for its lead complement inhibitor program and provide updated timing on pipeline plans, while also emphasizing what they see as potential competitive advantages in neuromuscula",
        "pubDate": "2026-02-13T15:27:55Z",
        "displayTime": "2026-02-13T15:27:55Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/marketbeat_955/3a7d9de1507b2bb93c83cd37ecba2c42",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "Dianthus Therapeutics logo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/bOZBJUmoR9_jOll6W6x5SA--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketbeat_955/3a7d9de1507b2bb93c83cd37ecba2c42.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/x12mntzRkKliOrJEkVp4Eg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/marketbeat_955/3a7d9de1507b2bb93c83cd37ecba2c42.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MarketBeat",
          "url": "https://www.marketbeat.com/"
        },
        "canonicalUrl": {
          "url": "https://www.marketbeat.com/instant-alerts/dianthus-therapeutics-conference-dnth-eyes-q2-2026-cidp-phase-3-interim-readout-expands-pipeline-plans-2026-02-13/?utm_source=yahoofinance&utm_medium=yahoofinance",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/dianthus-therapeutics-conference-dnth-eyes-152755948.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "DNTH"
            },
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "9887.HK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T14:57:40+00:00",
    "headline": "Wedbush Lifts PT on Biogen Inc. (BIIB) to $187 From $178 – Here’s Why",
    "summary": "Biogen Inc. (NASDAQ:BIIB) is one of the best medical research stocks to buy according to hedge funds. On February 10, Wedbush lifted the price target on Biogen Inc. (NASDAQ:BIIB) to $187 from $178, maintaining a Neutral rating on the shares. The firm told investors that Biogen Inc. (NASDAQ:BIIB) delivered another top-/bottom-line beat in its fiscal Q4 […]",
    "url": "https://finance.yahoo.com/news/wedbush-lifts-pt-biogen-inc-145740924.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "65a5626b-5d29-3e51-ae2e-584bcc711c3f",
      "content": {
        "id": "65a5626b-5d29-3e51-ae2e-584bcc711c3f",
        "contentType": "STORY",
        "title": "Wedbush Lifts PT on Biogen Inc. (BIIB) to $187 From $178 – Here’s Why",
        "description": "",
        "summary": "Biogen Inc. (NASDAQ:BIIB) is one of the best medical research stocks to buy according to hedge funds. On February 10, Wedbush lifted the price target on Biogen Inc. (NASDAQ:BIIB) to $187 from $178, maintaining a Neutral rating on the shares. The firm told investors that Biogen Inc. (NASDAQ:BIIB) delivered another top-/bottom-line beat in its fiscal Q4 […]",
        "pubDate": "2026-02-13T14:57:40Z",
        "displayTime": "2026-02-13T14:57:40Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/8095fdfd16ed3bef236befbd7ca2428c",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Biogen Inc. (BIIB): Among Small-Cap Healthcare Stocks Hedge Funds is Buying",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6ixRM3d_RV3w5hCozODMpg--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/8095fdfd16ed3bef236befbd7ca2428c.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/HIrwEXIPFTzVGiKAPI9LJA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/8095fdfd16ed3bef236befbd7ca2428c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/wedbush-lifts-pt-biogen-inc-145740924.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/wedbush-lifts-pt-biogen-inc-145740924.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T16:22:24+00:00",
    "headline": "Biogen Spotlights Lupus Pipeline at Piper Sandler Symposium: Litifilimab, Dapirolizumab in Focus",
    "summary": "Biogen (NASDAQ:BIIB) outlined its immunology and neurology development priorities during a virtual symposium hosted by Piper Sandler, with Dr. Diana Gallagher, head of clinical development for MS, immunology, and Alzheimer’s disease, discussing late-stage lupus programs and earlier-stage pipeline ef",
    "url": "https://www.marketbeat.com/instant-alerts/biogen-spotlights-lupus-pipeline-at-piper-sandler-symposium-litifilimab-dapirolizumab-in-focus-2026-02-13/?utm_source=yahoofinance&utm_medium=yahoofinance",
    "source": "MarketBeat",
    "provider": "yfinance",
    "raw": {
      "id": "3b424b69-0ecb-3551-a9c7-8afd7cbf9389",
      "content": {
        "id": "3b424b69-0ecb-3551-a9c7-8afd7cbf9389",
        "contentType": "STORY",
        "title": "Biogen Spotlights Lupus Pipeline at Piper Sandler Symposium: Litifilimab, Dapirolizumab in Focus",
        "description": "",
        "summary": "Biogen (NASDAQ:BIIB) outlined its immunology and neurology development priorities during a virtual symposium hosted by Piper Sandler, with Dr. Diana Gallagher, head of clinical development for MS, immunology, and Alzheimer’s disease, discussing late-stage lupus programs and earlier-stage pipeline ef",
        "pubDate": "2026-02-13T16:22:24Z",
        "displayTime": "2026-02-13T16:22:24Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/marketbeat_955/f6cb92b1ab1bc201dca4d0e2002bf5de",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "Biogen logo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_.adyKbwRRIZ45mLKmAUSg--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketbeat_955/f6cb92b1ab1bc201dca4d0e2002bf5de.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6T8EpjLAYHJzuBQ89qxUSg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/marketbeat_955/f6cb92b1ab1bc201dca4d0e2002bf5de.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MarketBeat",
          "url": "https://www.marketbeat.com/"
        },
        "canonicalUrl": {
          "url": "https://www.marketbeat.com/instant-alerts/biogen-spotlights-lupus-pipeline-at-piper-sandler-symposium-litifilimab-dapirolizumab-in-focus-2026-02-13/?utm_source=yahoofinance&utm_medium=yahoofinance",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/biogen-spotlights-lupus-pipeline-piper-162224103.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T11:00:00+00:00",
    "headline": "Lyell starts first-of-its-kind CAR-T trial; New coalition aims to boost European biotechs",
    "summary": "Lyell’s trial will test its experimental cancer cell therapy directly against marketed counterparts. Elsewhere, Biogen swapped board chairs and venture firms are joining up at a “pivotal time” for Europe.",
    "url": "https://www.biopharmadive.com/news/lyell-trial-biotech-europe-biogen-novocure-optum/812059/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "11d7fd94-e71d-3407-acc7-48f7cd8a345e",
      "content": {
        "id": "11d7fd94-e71d-3407-acc7-48f7cd8a345e",
        "contentType": "STORY",
        "title": "Lyell starts first-of-its-kind CAR-T trial; New coalition aims to boost European biotechs",
        "description": "",
        "summary": "Lyell’s trial will test its experimental cancer cell therapy directly against marketed counterparts. Elsewhere, Biogen swapped board chairs and venture firms are joining up at a “pivotal time” for Europe.",
        "pubDate": "2026-02-13T11:00:00Z",
        "displayTime": "2026-02-13T11:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YSECyFvzK8sIEiUW4LIicA--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/heEgXBvKL8Y58FXAXGaXPg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/lyell-trial-biotech-europe-biogen-novocure-optum/812059/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lyell-starts-first-kind-car-110000615.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LYEL"
            },
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "NVCR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T04:41:17+00:00",
    "headline": "1 Unpopular Stock That Deserves a Second Chance and 2 We Find Risky",
    "summary": "When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.",
    "url": "https://finance.yahoo.com/news/1-unpopular-stock-deserves-second-044117784.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "9f56ac9e-6883-34b3-a3a7-2ad0b39f4e21",
      "content": {
        "id": "9f56ac9e-6883-34b3-a3a7-2ad0b39f4e21",
        "contentType": "STORY",
        "title": "1 Unpopular Stock That Deserves a Second Chance and 2 We Find Risky",
        "description": "",
        "summary": "When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.",
        "pubDate": "2026-02-13T04:41:17Z",
        "displayTime": "2026-02-13T04:41:17Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/3e9471166a0d4ee8c41ab9eef8ac261c",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "BIIB Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/RI16PwyrPkPhFQpSFVHcpw--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/3e9471166a0d4ee8c41ab9eef8ac261c.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IR.mhpWSH09RyIH1vck_EQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/3e9471166a0d4ee8c41ab9eef8ac261c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/1-unpopular-stock-deserves-second-044117784.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/1-unpopular-stock-deserves-second-044117784.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ASGN"
            },
            {
              "symbol": "ALHC"
            },
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]